Cangrelor: Fixing Life or Just a Leak?

Affiliations

¹ Université Sorbonne Paris 6, ACTION Study Group, Institut de Cardiologie, Pitié-Salpêtrière (AP-HP), Paris, France.
² Université Sorbonne Paris 6, ACTION Study Group, Institut de Cardiologie, Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address: gilles.montalescot@aphp.fr.

Free article

Editorial

Mathieu Kerneis et al. JACC Cardiovasc Interv. 2016.

Free article

. 2016 Sep 26;9(18):1914-6.

doi: 10.1016/j.jcin.2016.07.025.

¹ Université Sorbonne Paris 6, ACTION Study Group, Institut de Cardiologie, Pitié-Salpêtrière (AP-HP), Paris, France.
² Université Sorbonne Paris 6, ACTION Study Group, Institut de Cardiologie, Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address: gilles.montalescot@aphp.fr.

No abstract available

Keywords: P2Y(12) antagonist; antiplatelet drug; stable coronary artery disease.

Comment on

Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Abtan J, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, Price MJ, Abnousi F, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL; CHAMPION PHOENIX Investigators. Abtan J, et al. JACC Cardiovasc Interv. 2016 Sep 26;9(18):1905-13. doi: 10.1016/j.jcin.2016.06.046. JACC Cardiovasc Interv. 2016. PMID: 27659566 Clinical Trial.